4 Best Small-Cap Surgical Robotics & Med-Device Stocks — May 2026
Pure-play surgical robotics small-caps are rare. The actual investable layer is robotics-adjacent specialty surgical devices: ablation, nerve repair, sleep-apnea implants. 5 names with capital-equipment-plus-recurring-consumables economics.
True 'surgical robotics' as a small-cap category is thin — Intuitive Surgical owns 80%+ of robot-assisted surgery and is firmly mid/large-cap. The investable small-cap layer is what we call 'robotics-adjacent specialty surgical devices': companies whose products participate in robot-assisted procedures or use capital-equipment-plus-recurring-consumables economics similar to surgical robotics.
We scored every small-cap medical-device name with surgical or robot-assisted-procedure exposure. Here are the 5 highest-scoring, with explicit framing of how each fits the broader robotics economic model.
Why Small-Cap Surgical Robotics & Med-Device Is Different
- True surgical-robotics small-caps are rare — Intuitive Surgical owns the volume; small-caps mostly play in adjacent specialty-surgical or capital-equipment niches.
- Capital-equipment-plus-recurring-consumables is the desirable model — placement of a system creates an annuity of consumables/services. PRCT and INSP fit this best on the list.
- FDA approval is the dominant binary — most names have at least one PMA or 510(k) milestone in the next 24 months that materially affects valuation.
- Reimbursement and coding decisions matter as much as clinical results — CMS coverage, CPT codes, and commercial-payer policies often gate adoption rates more than clinical efficacy data.
Our scoring rewards balance-sheet quality, capital efficiency, and growth quality. For specialty med-device names, gross margin and revenue-growth-vs-dilution trajectory are the most informative metrics.
Top 4 Small-Cap Surgical Robotics & Med-Device Stocks by Fundamental Score — May 2026
Get picks like these first.
Free weekly digest — top movers, score changes, new small-cap opportunities. No spam, unsubscribe anytime.
1. PROCEPT BioRobotics Corporation (PRCT) — Score: 71.2 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +37.2% | 60 |
| Gross Margin | 63.7% | 91 |
| Cash Runway | 70 months | 100 |
| Debt/Equity | 21.45 | 83 |
| P/S Ratio | 5.1x | 70 |
| Rule of 40 | 3.5 | 25 |
| Insider Ownership | 4.4% | 35 |
| 12m Dilution | +2.0% | 88 |
What drives the score: PROCEPT BioRobotics makes the AquaBeam Robotic System for Aquablation therapy of benign prostatic hyperplasia (BPH). Razor-and-blade model: capital-equipment placements drive recurring single-use treatment kits. Strong installed-base growth, profitable on contribution margin.
Key risk: Capital-equipment placement cycle dominates revenue smoothness. Surgeon-training and credentialing pace limits utilization growth. Recurring revenue is concentrated in single-use treatment kits — pricing pressure from payers or competing technologies (drug therapies, prostate artery embolization) would compress recurring economics.
Market cap: $1.57B. Industry: Medical Devices.
2. AtriCure, Inc. (ATRC) — Score: 69.4 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +14.9% | 24 |
| Gross Margin | 75.0% | 100 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | 14.92 | 88 |
| P/S Ratio | 2.8x | 91 |
| Rule of 40 | 13.1 | 40 |
| Insider Ownership | 3.7% | 30 |
| 12m Dilution | +0.6% | 96 |
What drives the score: AtriCure makes ablation and clip devices for surgical treatment of atrial fibrillation. Lower on the robotics curve than Intuitive Surgical, but established surgical-tools revenue with single-digit growth and improving margins.
Key risk: Mature surgical-tools business with single-digit growth. Atrial-fibrillation surgical-ablation is a subset of overall AFib treatment (catheter ablation is dominant); structural growth path is convex-on-concomitant-procedure-volume rather than primary-procedure share.
Market cap: $1.48B. Industry: Medical Instruments & Supplies.
3. AxoGen, Inc. (AXGN) — Score: 60.5 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +20.2% | 32 |
| Gross Margin | 74.3% | 100 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | 52.49 | 53 |
| P/S Ratio | 7.4x | 58 |
| Rule of 40 | 16.7 | 45 |
| Insider Ownership | 2.6% | 21 |
| 12m Dilution | +14.0% | 28 |
What drives the score: AxoGen makes peripheral-nerve repair grafts (Avance Nerve Graft, AxoGuard). Adjacent to surgical robotics in the sense that robotic-assisted procedures often include nerve-sparing steps. Specialty product, growing surgeon-adoption base.
Key risk: Specialty product (peripheral nerve repair) with growing surgeon-adoption base. Still relatively narrow indication-mix; broader applications (oral-maxillofacial, breast reconstruction) drive expansion. Not directly a robotics play.
Market cap: $1.66B. Industry: Medical Devices.
Still reading? Get the full weekly rundown.
Every Monday: fresh score changes, new names crossing 80+, and context you won't find in the screener.
4. Avanos Medical, Inc. (AVNS) — Score: 60.5 | Grade: SOLID
| Metric | Value | Score |
|---|---|---|
| Revenue Growth YoY | +1.9% | 3 |
| Gross Margin | 50.5% | 71 |
| Cash Runway | >36 months | 100 |
| Debt/Equity | 16.59 | 87 |
| P/S Ratio | 0.9x | 100 |
| Rule of 40 | 4.1 | 26 |
| Insider Ownership | 4.0% | 32 |
| 12m Dilution | +0.6% | 97 |
What drives the score: Avanos Medical makes surgical pain-management (ON-Q, Game Ready) and respiratory devices. Mature business, low single-digit growth, modest margins. Adjacent to operating-room economics rather than robotics specifically.
Key risk: Mature business with low single-digit growth and modest margins. Structural growth less of a story than capital-return discipline. Not directly a robotics play.
Market cap: $625M. Industry: Medical Devices.
What these 4 stocks have in common
-
'Surgical robotics' is more aspirational than literal at the small-cap level. Of five names, only PRCT runs a true robotic-platform model (AquaBeam Robotic System). The others are surgical specialty devices that participate in robot-assisted contexts.
-
Capital-equipment-plus-consumables economics matter more than 'robotics' branding. PRCT and INSP both have placement-driven recurring revenue. ATRC, AXGN, AVNS run more conventional disposable-device models.
-
FDA-binary risk is concentrated. Each name has a near-term FDA decision or label-expansion that meaningfully affects 12-24 month revenue trajectory.
What's not on this list — and why
- Intuitive Surgical (ISRG) — $200B+ market cap. The dominant surgical-robotics company, da Vinci platform. Out of small-cap range by 100x.
- Stryker (SYK) — large-cap; Mako orthopedic robot is real but a fraction of corporate revenue.
- Globus Medical (GMED) — $9B+ market cap. ExcelsiusGPS spine robot. Out of small-cap range.
- Vicarious Surgical (RBOT) — small-cap but has had repeated balance-sheet stress; not on this list due to fundamentals deterioration.
- Asensus Surgical (ASXC) — micro-cap, in restructuring.
True pure-play surgical-robotics public-equity exposure at the small-cap level is minimal. Investors building this exposure typically need to either accept that ISRG is the category benchmark (mid/large-cap) or include the broader specialty-surgical-device set on this list.
How to use this data
These scores measure financial health, capital efficiency, and dilution discipline. For surgical-device names:
- Track FDA-decision calendar and label-expansion approvals — material for each name
- For PRCT and INSP, watch quarterly system placements + utilization metrics; the consumables annuity follows
- For ATRC, AXGN, AVNS, growth quality (organic vs M&A) is the differentiator
- Across all names, gross margin trajectory is the leading indicator of pricing power
SmallCapScanner scores are calculated algorithmically based on 8 fundamental factors. They measure financial health, not future performance. See /how-it-works for the full methodology.
Track these stocks and 2,200+ others on our screener. Set alerts to know when a score crosses your threshold, or compare two tickers directly on /compare.